Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022
•Respiratory syncytial virus (RSV) is an important pathogen globally.•The burden of RSV illness is highest in low/middle-income countries (LMICs).•In April 2022, WHO convened a meeting to discuss the economics of RSV prevention.•We reviewed cost-effectiveness analyses of RSV prevention in LMICs.•We...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2023-11, Vol.41 (48), p.7047-7059 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7059 |
|---|---|
| container_issue | 48 |
| container_start_page | 7047 |
| container_title | Vaccine |
| container_volume | 41 |
| creator | Fitzpatrick, Meagan C. Laufer, Rachel S. Baral, Ranju Driscoll, Amanda J. Feikin, Daniel R. Fleming, Jessica A. Jit, Mark Kim, Sonnie Koltai, Mihaly Li, You Li, Xiao Nair, Harish Neuzil, Kathleen M. Pecenka, Clint Sparrow, Erin Srikantiah, Padmini Ortiz, Justin R. |
| description | •Respiratory syncytial virus (RSV) is an important pathogen globally.•The burden of RSV illness is highest in low/middle-income countries (LMICs).•In April 2022, WHO convened a meeting to discuss the economics of RSV prevention.•We reviewed cost-effectiveness analyses of RSV prevention in LMICs.•We provided recommendations for future data gathering to address data limitations.
Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting. |
| doi_str_mv | 10.1016/j.vaccine.2023.09.040 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2870994627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23011106</els_id><sourcerecordid>2870994627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-84460c8fce305052e6cd7807592735856fd1f97de9f81c903b10f156569a62f13</originalsourceid><addsrcrecordid>eNqFkcGKFDEQhoMo7jj6CErAi4ftttKddCcnWRZ1hYUFUfQWetMVNkNP0ibpkbn5Dr6HD-WTmHFGD14MgUDx_X-l6ifkKYOaAeteburdYIzzWDfQtDWoGjjcIysm-7ZqBJP3yQqajlecwecz8iilDQCIlqmH5Kzty-ECVuTHe5xDzDRYmu-Qfrq6oRnNnXdmmKgJPi1THrILnpZ7IHA3TMupYmnENLs45BD3NO292WdXdDsXl0TniDv0v0kTUqZoLZrsSg1Tos7TKXyt6OBHunXjOGHlvAlbLPDic3SYzunFHN1E-5_fvstzWuZsHpMHdpgSPjm9a_LxzesPl1fV9c3bd5cX15XhHHIlOe_ASGuwBQGiwc6MvYReqKZvhRSdHZlV_YjKSmYUtLcMLBOd6NTQNZa1a_Li6DvH8GXBlPXWJYPTNHgMS9KN7EEp3hW7NXn-D7oJS_Tld4VSjHPJOlkocaRMDClFtLqMth3iXjPQh0D1Rp8C1YdANShdAi26Zyf35XaL41_VnwQL8OoIYFnHzmHUyTj0BkcXy7r1GNx_WvwCWdG2KQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891448168</pqid></control><display><type>article</type><title>Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Fitzpatrick, Meagan C. ; Laufer, Rachel S. ; Baral, Ranju ; Driscoll, Amanda J. ; Feikin, Daniel R. ; Fleming, Jessica A. ; Jit, Mark ; Kim, Sonnie ; Koltai, Mihaly ; Li, You ; Li, Xiao ; Nair, Harish ; Neuzil, Kathleen M. ; Pecenka, Clint ; Sparrow, Erin ; Srikantiah, Padmini ; Ortiz, Justin R.</creator><creatorcontrib>Fitzpatrick, Meagan C. ; Laufer, Rachel S. ; Baral, Ranju ; Driscoll, Amanda J. ; Feikin, Daniel R. ; Fleming, Jessica A. ; Jit, Mark ; Kim, Sonnie ; Koltai, Mihaly ; Li, You ; Li, Xiao ; Nair, Harish ; Neuzil, Kathleen M. ; Pecenka, Clint ; Sparrow, Erin ; Srikantiah, Padmini ; Ortiz, Justin R.</creatorcontrib><description>•Respiratory syncytial virus (RSV) is an important pathogen globally.•The burden of RSV illness is highest in low/middle-income countries (LMICs).•In April 2022, WHO convened a meeting to discuss the economics of RSV prevention.•We reviewed cost-effectiveness analyses of RSV prevention in LMICs.•We provided recommendations for future data gathering to address data limitations.
Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.09.040</identifier><identifier>PMID: 37777450</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Cost analysis ; Cost effectiveness ; Cost-Benefit Analysis ; Cost-Effectiveness Analysis ; Developing Countries ; Disease prevention ; Economics ; Epidemiology ; Estimates ; Fatalities ; Geography ; Global health ; Health promotion ; High income ; Hospitalization ; Hospitals ; Humans ; Immunization ; Industrialized nations ; Infant ; Intervention ; LDCs ; Licenses ; Monoclonal antibodies ; Monoclonal antibody ; Morbidity ; Mortality ; Older people ; Parameter identification ; Parameterization ; Pneumonia ; Prevention ; R&D ; Referral and Consultation ; Regulatory approval ; Research & development ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - epidemiology ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Syncytial Virus, Human ; Sensitivity analysis ; Systematic review ; Vaccine ; Vaccines ; Viruses ; World Health Organization</subject><ispartof>Vaccine, 2023-11, Vol.41 (48), p.7047-7059</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Nov 22, 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-84460c8fce305052e6cd7807592735856fd1f97de9f81c903b10f156569a62f13</citedby><cites>FETCH-LOGICAL-c440t-84460c8fce305052e6cd7807592735856fd1f97de9f81c903b10f156569a62f13</cites><orcidid>0000-0002-3138-5965</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2891448168?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997,64387,64389,64391,72471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37777450$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fitzpatrick, Meagan C.</creatorcontrib><creatorcontrib>Laufer, Rachel S.</creatorcontrib><creatorcontrib>Baral, Ranju</creatorcontrib><creatorcontrib>Driscoll, Amanda J.</creatorcontrib><creatorcontrib>Feikin, Daniel R.</creatorcontrib><creatorcontrib>Fleming, Jessica A.</creatorcontrib><creatorcontrib>Jit, Mark</creatorcontrib><creatorcontrib>Kim, Sonnie</creatorcontrib><creatorcontrib>Koltai, Mihaly</creatorcontrib><creatorcontrib>Li, You</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Nair, Harish</creatorcontrib><creatorcontrib>Neuzil, Kathleen M.</creatorcontrib><creatorcontrib>Pecenka, Clint</creatorcontrib><creatorcontrib>Sparrow, Erin</creatorcontrib><creatorcontrib>Srikantiah, Padmini</creatorcontrib><creatorcontrib>Ortiz, Justin R.</creatorcontrib><title>Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Respiratory syncytial virus (RSV) is an important pathogen globally.•The burden of RSV illness is highest in low/middle-income countries (LMICs).•In April 2022, WHO convened a meeting to discuss the economics of RSV prevention.•We reviewed cost-effectiveness analyses of RSV prevention in LMICs.•We provided recommendations for future data gathering to address data limitations.
Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.</description><subject>Cost analysis</subject><subject>Cost effectiveness</subject><subject>Cost-Benefit Analysis</subject><subject>Cost-Effectiveness Analysis</subject><subject>Developing Countries</subject><subject>Disease prevention</subject><subject>Economics</subject><subject>Epidemiology</subject><subject>Estimates</subject><subject>Fatalities</subject><subject>Geography</subject><subject>Global health</subject><subject>Health promotion</subject><subject>High income</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunization</subject><subject>Industrialized nations</subject><subject>Infant</subject><subject>Intervention</subject><subject>LDCs</subject><subject>Licenses</subject><subject>Monoclonal antibodies</subject><subject>Monoclonal antibody</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Older people</subject><subject>Parameter identification</subject><subject>Parameterization</subject><subject>Pneumonia</subject><subject>Prevention</subject><subject>R&D</subject><subject>Referral and Consultation</subject><subject>Regulatory approval</subject><subject>Research & development</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - epidemiology</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory Syncytial Virus, Human</subject><subject>Sensitivity analysis</subject><subject>Systematic review</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Viruses</subject><subject>World Health Organization</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcGKFDEQhoMo7jj6CErAi4ftttKddCcnWRZ1hYUFUfQWetMVNkNP0ibpkbn5Dr6HD-WTmHFGD14MgUDx_X-l6ifkKYOaAeteburdYIzzWDfQtDWoGjjcIysm-7ZqBJP3yQqajlecwecz8iilDQCIlqmH5Kzty-ECVuTHe5xDzDRYmu-Qfrq6oRnNnXdmmKgJPi1THrILnpZ7IHA3TMupYmnENLs45BD3NO292WdXdDsXl0TniDv0v0kTUqZoLZrsSg1Tos7TKXyt6OBHunXjOGHlvAlbLPDic3SYzunFHN1E-5_fvstzWuZsHpMHdpgSPjm9a_LxzesPl1fV9c3bd5cX15XhHHIlOe_ASGuwBQGiwc6MvYReqKZvhRSdHZlV_YjKSmYUtLcMLBOd6NTQNZa1a_Li6DvH8GXBlPXWJYPTNHgMS9KN7EEp3hW7NXn-D7oJS_Tld4VSjHPJOlkocaRMDClFtLqMth3iXjPQh0D1Rp8C1YdANShdAi26Zyf35XaL41_VnwQL8OoIYFnHzmHUyTj0BkcXy7r1GNx_WvwCWdG2KQ</recordid><startdate>20231122</startdate><enddate>20231122</enddate><creator>Fitzpatrick, Meagan C.</creator><creator>Laufer, Rachel S.</creator><creator>Baral, Ranju</creator><creator>Driscoll, Amanda J.</creator><creator>Feikin, Daniel R.</creator><creator>Fleming, Jessica A.</creator><creator>Jit, Mark</creator><creator>Kim, Sonnie</creator><creator>Koltai, Mihaly</creator><creator>Li, You</creator><creator>Li, Xiao</creator><creator>Nair, Harish</creator><creator>Neuzil, Kathleen M.</creator><creator>Pecenka, Clint</creator><creator>Sparrow, Erin</creator><creator>Srikantiah, Padmini</creator><creator>Ortiz, Justin R.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3138-5965</orcidid></search><sort><creationdate>20231122</creationdate><title>Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022</title><author>Fitzpatrick, Meagan C. ; Laufer, Rachel S. ; Baral, Ranju ; Driscoll, Amanda J. ; Feikin, Daniel R. ; Fleming, Jessica A. ; Jit, Mark ; Kim, Sonnie ; Koltai, Mihaly ; Li, You ; Li, Xiao ; Nair, Harish ; Neuzil, Kathleen M. ; Pecenka, Clint ; Sparrow, Erin ; Srikantiah, Padmini ; Ortiz, Justin R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-84460c8fce305052e6cd7807592735856fd1f97de9f81c903b10f156569a62f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cost analysis</topic><topic>Cost effectiveness</topic><topic>Cost-Benefit Analysis</topic><topic>Cost-Effectiveness Analysis</topic><topic>Developing Countries</topic><topic>Disease prevention</topic><topic>Economics</topic><topic>Epidemiology</topic><topic>Estimates</topic><topic>Fatalities</topic><topic>Geography</topic><topic>Global health</topic><topic>Health promotion</topic><topic>High income</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunization</topic><topic>Industrialized nations</topic><topic>Infant</topic><topic>Intervention</topic><topic>LDCs</topic><topic>Licenses</topic><topic>Monoclonal antibodies</topic><topic>Monoclonal antibody</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Older people</topic><topic>Parameter identification</topic><topic>Parameterization</topic><topic>Pneumonia</topic><topic>Prevention</topic><topic>R&D</topic><topic>Referral and Consultation</topic><topic>Regulatory approval</topic><topic>Research & development</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - epidemiology</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory Syncytial Virus, Human</topic><topic>Sensitivity analysis</topic><topic>Systematic review</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Viruses</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fitzpatrick, Meagan C.</creatorcontrib><creatorcontrib>Laufer, Rachel S.</creatorcontrib><creatorcontrib>Baral, Ranju</creatorcontrib><creatorcontrib>Driscoll, Amanda J.</creatorcontrib><creatorcontrib>Feikin, Daniel R.</creatorcontrib><creatorcontrib>Fleming, Jessica A.</creatorcontrib><creatorcontrib>Jit, Mark</creatorcontrib><creatorcontrib>Kim, Sonnie</creatorcontrib><creatorcontrib>Koltai, Mihaly</creatorcontrib><creatorcontrib>Li, You</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Nair, Harish</creatorcontrib><creatorcontrib>Neuzil, Kathleen M.</creatorcontrib><creatorcontrib>Pecenka, Clint</creatorcontrib><creatorcontrib>Sparrow, Erin</creatorcontrib><creatorcontrib>Srikantiah, Padmini</creatorcontrib><creatorcontrib>Ortiz, Justin R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fitzpatrick, Meagan C.</au><au>Laufer, Rachel S.</au><au>Baral, Ranju</au><au>Driscoll, Amanda J.</au><au>Feikin, Daniel R.</au><au>Fleming, Jessica A.</au><au>Jit, Mark</au><au>Kim, Sonnie</au><au>Koltai, Mihaly</au><au>Li, You</au><au>Li, Xiao</au><au>Nair, Harish</au><au>Neuzil, Kathleen M.</au><au>Pecenka, Clint</au><au>Sparrow, Erin</au><au>Srikantiah, Padmini</au><au>Ortiz, Justin R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-11-22</date><risdate>2023</risdate><volume>41</volume><issue>48</issue><spage>7047</spage><epage>7059</epage><pages>7047-7059</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Respiratory syncytial virus (RSV) is an important pathogen globally.•The burden of RSV illness is highest in low/middle-income countries (LMICs).•In April 2022, WHO convened a meeting to discuss the economics of RSV prevention.•We reviewed cost-effectiveness analyses of RSV prevention in LMICs.•We provided recommendations for future data gathering to address data limitations.
Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>37777450</pmid><doi>10.1016/j.vaccine.2023.09.040</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3138-5965</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2023-11, Vol.41 (48), p.7047-7059 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2870994627 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Cost analysis Cost effectiveness Cost-Benefit Analysis Cost-Effectiveness Analysis Developing Countries Disease prevention Economics Epidemiology Estimates Fatalities Geography Global health Health promotion High income Hospitalization Hospitals Humans Immunization Industrialized nations Infant Intervention LDCs Licenses Monoclonal antibodies Monoclonal antibody Morbidity Mortality Older people Parameter identification Parameterization Pneumonia Prevention R&D Referral and Consultation Regulatory approval Research & development Respiratory syncytial virus Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus, Human Sensitivity analysis Systematic review Vaccine Vaccines Viruses World Health Organization |
| title | Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T11%3A08%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Report%20of%20the%20WHO%20technical%20consultation%20on%20the%20evaluation%20of%20respiratory%20syncytial%20virus%20prevention%20cost%20effectiveness%20in%20low-%20and%20middle-income%20countries,%20April%207%E2%80%938,%202022&rft.jtitle=Vaccine&rft.au=Fitzpatrick,%20Meagan%20C.&rft.date=2023-11-22&rft.volume=41&rft.issue=48&rft.spage=7047&rft.epage=7059&rft.pages=7047-7059&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.09.040&rft_dat=%3Cproquest_cross%3E2870994627%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2891448168&rft_id=info:pmid/37777450&rft_els_id=S0264410X23011106&rfr_iscdi=true |